---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343446"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2026-08-11T11:35:09+00:00"
generated_at: "2026-08-11T11:40:17.149392+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sagimet posts Q2 2026 net loss of $14.0M; $257.6M cash funds operations through 2028

## Summary
- Q2 2026 net loss $14.0M vs $10.4M in Q2 2025; H1 2026 net loss $24.6M vs $28.6M.
- Cash, equivalents and marketable securities $257.6M as of June 30, 2026, expected to fund operations through 2028.
- Phase 3 trial of denifanstat in moderate to severe acne on track to initiate in U.S. in H2 2026.
- Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned before end of 2026.
- Completed $175.0M equity financing in April 2026; added to Russell 3000 and Russell 2000 indexes in June.

## SEC filing metadata
- accession: 0001193125-26-343446
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2026-08-11T11:35:09+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/0001193125-26-343446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/d36435d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343446
- JSON: https://secwatch.observer/filing/0001193125-26-343446.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.